Trial site
Klinische Forschung Hamburg GmbH
Hamburg, 20253, GermanyNot linked to an institution yet
- 14running trials
- 18closed trials
The trials here
What the 32 trials at this site are about, from their registry records.
- Phase
- Phase 322 trials
- Phase 25 trials
- Phase 44 trials
- Phase 11 trial
- Status
- Completed18 trials
- Recruiting7 trials
- Active, not recruiting6 trials
- Not yet recruiting1 trial
- Lead sponsor
- Pfizer4 trials
- Dr. Willmar Schwabe GmbH & Co. KG2 trials
- Eli Lilly and Company2 trials
- ModernaTX, Inc.2 trials
- AbbVie1 trial
- and 21 more
Running trials
Recruiting
A Study to evaluate effect of AZD6234 in adult participants with Type 2 Diabetes Mellitus and obesity or overweight
2025-524616-11-00· Phase 3· AstraZeneca AB· Source
Not yet recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications
2026-527531-33-00· Phase 3· Cidara Therapeutics Inc.· Source
Recruiting
A study on the efficacy of a vaccine against influenza in adults ≥65 years of age
2026-526682-14-00· Phase 3· GlaxoSmithKline Biologicals· Source
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725· Phase 3· AstraZeneca· Source
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653· Phase 3· Pfizer· Source
Active, not recruiting
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850· Phase 3· Pfizer· Source
Active, not recruiting
Silexan® in mild to moderate major depressive disorder
2025-521744-37-00· Phase 3· Dr. Willmar Schwabe GmbH & Co. KG· Source
Active, not recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343· Phase 3· Amgen· Source
Active, not recruiting
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837· Phase 1· GlaxoSmithKline· Source
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· Phase 3· Anthos Therapeutics, Inc.· Source
Recruiting
Controlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irritable bowel syndrome (IBS-D) and patients with mixed-type irritable bowel syndrome (IBS-M)
2024-514892-16-00· Phase 4· REPHA GmbH Biologische Arzneimittel· Source
Recruiting
Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with living bacteria of E. coli DSM 17252 (Symbioflor®2) in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)
2024-512104-19-00· Phase 4· SymbioPharm GmbH· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A trial to find the effect of Ginkgo biloba extract EGb 761® and how safe it is in participants with cognitive impairment associated with post COVID-19 syndrome
2024-517199-39-00· Phase 2· Dr. Willmar Schwabe GmbH & Co. KG· Source
Completed
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia
2024-511057-22-00· Phase 3· Janssen Cilag International· Source
Completed
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder
NCT06029439· Phase 3· Neumora Therapeutics Inc.· Source
Completed
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
NCT06602024· Phase 3· ModernaTX, Inc.· Source
Completed
A proof of concept and dose-finding study of XXB750 in patients with heart failure
2023-504678-39-00· Phase 2· Novartis Pharma AG· Source
Completed
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
NCT06058039· Phase 3· Neumora Therapeutics, Inc.· Source
Completed
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older
NCT06015282· Phase 3· Seqirus· Source
Completed
The Celljuvant study, A phase 3 Immunogenicity and Safety Study of aQIVc HD Vaccine in Adults aged 50 years and older.
2023-503763-42-00· Phase 3· Seqirus UK Limited· Source
Completed
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
NCT05748483· Phase 3· AbbVie· Source
Completed
Efficacy and Tolerability of Tasipimidine in Sleepless Patients
NCT06956495· Phase 2· Orion Corporation, Orion Pharma· Source
Completed
The RADIAL study: A clinical trial to learn more about the benefits and the acceptability of trials that include technology to centre the trial around the participant, known as decentralised, and hybrid clinical trials compared to standard clinical trials that take place in hospitals or in research centres, in patients with type 2 diabetes mellitus treated with Toujeo®, a drug to help manage blood sugar levels.
2022-500449-26-00· Phase 4· University Medical Center Utrecht· Source
Completed
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke
NCT05643573· Phase 3· Bayer AG· Source
Completed
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
NCT05566639· Phase 3· ModernaTX, Inc.· Source
Completed
A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)
NCT05258071· Phase 2· Integrative Research Laboratories AB· Source
Completed
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
NCT05217927· Phase 4· Pfizer· Source
Completed
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
NCT05318976· Phase 2· Inmune Bio, Inc.· Source
Completed
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
NCT05079919· Phase 3· Ionis Pharmaceuticals, Inc.· Source
Completed
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT03422822· Phase 3· Pfizer· Source
Report an error